Literature DB >> 17185376

Role of hypothalamic adenosine 5'-monophosphate-activated protein kinase in the impaired counterregulatory response induced by repetitive neuroglucopenia.

Thierry Alquier1, Junji Kawashima, Youki Tsuji, Barbara B Kahn.   

Abstract

Antecedent hypoglycemia blunts counterregulatory responses that normally restore glycemia, a phenomenon known as hypoglycemia-associated autonomic failure (HAAF). The mechanisms leading to impaired counterregulatory responses are largely unknown. Hypothalamic AMP-activated protein kinase (AMPK) acts as a glucose sensor. To determine whether failure to activate AMPK could be involved in the etiology of HAAF, we developed a model of HAAF using repetitive intracerebroventricular (icv) injection of 2-deoxy-D-glucose (2DG) resulting in transient neuroglucopenia in normal rats. Ten minutes after a single icv injection of 2DG, both alpha1- and alpha2-AMPK activities were increased 30-50% in arcuate and ventromedial/dorsomedial hypothalamus but not in other hypothalamic regions, hindbrain, or cortex. Increased AMPK activity persisted in arcuate hypothalamus at 60 min after 2DG injection when serum glucagon and corticosterone levels were increased 2.5- to 3.4-fold. When 2DG was injected icv daily for 4 d, hypothalamic alpha1- and alpha2-AMPK responses were markedly blunted in arcuate hypothalamus, and alpha1-AMPK was also blunted in mediobasal hypothalamus 10 min after 2DG on d 4. Both AMPK isoforms were activated normally in arcuate hypothalamus at 60 min. Counterregulatory hormone responses were impaired by recurrent neuroglucopenia and were partially restored by icv injection of 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside, an AMPK activator, before 2DG. Glycogen content increased 2-fold in hypothalamus after recurrent neuroglucopenia, suggesting that glycogen supercompensation could be involved in down-regulating the AMPK glucose-sensing pathway in HAAF. Thus, activation of hypothalamic AMPK may be important for the full counterregulatory hormone response to neuroglucopenia. Furthermore, impaired or delayed AMPK activation in specific hypothalamic regions may play a critical role in the etiology of HAAF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185376     DOI: 10.1210/en.2006-1039

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  39 in total

Review 1.  Metabolic Alterations Associated to Brain Dysfunction in Diabetes.

Authors:  João M N Duarte
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Glycogen Supercompensation in the Rat Brain After Acute Hypoglycemia is Independent of Glucose Levels During Recovery.

Authors:  João M N Duarte; Florence D Morgenthaler; Rolf Gruetter
Journal:  Neurochem Res       Date:  2017-01-12       Impact factor: 3.996

Review 3.  Targeting the CNS to treat type 2 diabetes.

Authors:  Darleen A Sandoval; Silvana Obici; Randy J Seeley
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 4.  Noninvasive measurement of brain glycogen by nuclear magnetic resonance spectroscopy and its application to the study of brain metabolism.

Authors:  Nolawit Tesfaye; Elizabeth R Seaquist; Gülin Oz
Journal:  J Neurosci Res       Date:  2011-07-05       Impact factor: 4.164

Review 5.  Hypothalamic AMPK: a canonical regulator of whole-body energy balance.

Authors:  Miguel López; Rubén Nogueiras; Manuel Tena-Sempere; Carlos Diéguez
Journal:  Nat Rev Endocrinol       Date:  2016-05-20       Impact factor: 43.330

Review 6.  Role of AMP-activated protein kinase in the control of appetite.

Authors:  B Kola
Journal:  J Neuroendocrinol       Date:  2008-04-28       Impact factor: 3.627

7.  Glucose sensing during hypoglycemia: lessons from the lab.

Authors:  Rory McCrimmon
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

8.  Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes.

Authors:  X Fan; Y Ding; S Brown; L Zhou; M Shaw; M C Vella; H Cheng; E C McNay; R S Sherwin; R J McCrimmon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-08       Impact factor: 3.619

9.  Human brain glycogen metabolism during and after hypoglycemia.

Authors:  Gülin Oz; Anjali Kumar; Jyothi P Rao; Christopher T Kodl; Lisa Chow; Lynn E Eberly; Elizabeth R Seaquist
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

10.  Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia.

Authors:  Erwin C Puente; Julie Silverstein; Adam J Bree; Daniel R Musikantow; David F Wozniak; Susan Maloney; Dorit Daphna-Iken; Simon J Fisher
Journal:  Diabetes       Date:  2010-01-19       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.